

Active Ingredient: Betamethasone dipropionate 



Dosage Form; Route: Cream; topical 



Recommended Studies: Two studies 





1.Type of study: Pilot vasoconstrictor study

Design: A pilot dose duration-response study using the reference product

Strength: 0.05% (as betamethasone)

Subjects: Healthy males and non-pregnant, non-lactating females, general population

Additional Comments: Please refer to the guidance “Topical Dermatological Corticosteroids:
In Vivo Bioequivalence” available at:
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070234.pdf.



2.Type of study: Pivotal vasoconstrictor study

Design: A pivotal bioequivalence study

Strength: 0.05% (as betamethasone)

Subjects: Healthy males and non-pregnant, non-lactating females, general population

Additional Comments: Please refer to the guidance above








Analytes to measure (in appropriate biological fluid): Not applicable 



Bioequivalence based on (90% CI): Pivotal vasoconstrictor study 



Waiver request of in vivo testing: Not applicable 



Dissolution test method and sample times: Not applicable 


